HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 276, Issue 21, 17718-17726, May 25, 2001

This Article Full Text Full Text (PDF) All Versions of this Article: 276/21/17718    most recent M100736200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sidis, Y. Articles by Keutmann, H. T. Search for Related Content PubMed PubMed Citation Articles by Sidis, Y. Articles by Keutmann, H. T. Social Bookmarking                      What's this?

Follistatin: Essential Role for the N-terminal Domain in Activin Binding and Neutralization^*

Yisrael Sidis, Alan L. Schneyer, Patrick M. Sluss, Leslie N. Johnson^§, and Henry T. Keutmann^§¶

From the  Reproductive Endocrine Unit and National Center for Infertility Research and the ^§ Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114

Follistatin is recognized to be an important regulator of cellular differentiation and secretion through its potent ability to bind and bioneutralize activin with which it is colocalized in many tissue systems. The 288-residue follistatin molecule is comprised of a 63-residue N-terminal segment followed by three repeating 10-cysteine "follistatin domains" also represented in several extracellular matrix proteins. We have used chemical modifications and mutational analyses to define structural requirements for follistatin bioactivity that previously have not been investigated systematically. Mutant follistatins were stably expressed from Chinese hamster ovary cell cultures and assayed for activin binding in a solid-phase competition assay. Biological activities were determined by inhibition of activin-mediated transcriptional activity and by suppression of follicle-stimulating hormone secretion by cultured anterior pituitary cells. Deletion of the entire N-terminal domain, disruption of N-terminal disulfides, and deletion of the first two residues each reduced activin binding to <5 % of expressed wild-type follistatin and abolished the ability of the respective mutants to suppress activin-mediated responses in both bioassay systems. Hence, the three follistatin domains inherently lack the ability to bind or neutralize activin. Activin binding was impaired after oxidation of at least one tryptophan, at position 4, in FS-288. Mutation of Trp to Ala or Asp at either positions 4 or 36 eliminated activin binding and bioactivity. Mutation of a third hydrophobic residue, Phe-52, reduced binding to 20%, whereas substitutions for the individual Lys and Arg residues in the N-terminal region were tolerated. These results establish that hydrophobic residues within the N-terminal domain constitute essential activin-binding determinants in the follistatin molecule. The correlation among the effects of mutation on activin binding, activin transcriptional responses, and follicle-stimulating hormone secretion substantiates the concept that, at least in the pituitary, the biological activity of follistatin is attributable to its ability to bind and bioneutralize activin.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				R. Stamler, H. T. Keutmann, Y. Sidis, C. Kattamuri, A. Schneyer, and T. B. Thompson The Structure of FSTL3{middle dot}Activin A Complex: DIFFERENTIAL BINDING OF N-TERMINAL DOMAINS INFLUENCES FOLLISTATIN-TYPE ANTAGONIST SPECIFICITY J. Biol. Chem., November 21, 2008; 283(47): 32831 - 32838. [Abstract] [Full Text] [PDF]

				A. L. Schneyer, Y. Sidis, A. Gulati, J. L. Sun, H. Keutmann, and P. A. Krasney Differential Antagonism of Activin, Myostatin and Growth and Differentiation Factor 11 by Wild-Type and Mutant Follistatin Endocrinology, September 1, 2008; 149(9): 4589 - 4595. [Abstract] [Full Text] [PDF]

				S. Saito, Y. Sidis, A. Mukherjee, Y. Xia, and A. Schneyer Differential Biosynthesis and Intracellular Transport of Follistatin Isoforms and Follistatin-Like-3 Endocrinology, December 1, 2005; 146(12): 5052 - 5062. [Abstract] [Full Text] [PDF]

				Y. Sidis, A. L. Schneyer, and H. T. Keutmann Heparin and Activin-Binding Determinants in Follistatin and FSTL3 Endocrinology, January 1, 2005; 146(1): 130 - 136. [Abstract] [Full Text] [PDF]

				J R V Silva, R van den Hurk, H T A van Tol, B A J Roelen, and J R Figueiredo Gene expression and protein localisation for activin-A, follistatin and activin receptors in goat ovaries J. Endocrinol., November 1, 2004; 183(2): 405 - 415. [Abstract] [Full Text] [PDF]

				H. T. Keutmann, A. L. Schneyer, and Y. Sidis The Role of Follistatin Domains in Follistatin Biological Action Mol. Endocrinol., January 1, 2004; 18(1): 228 - 240. [Abstract] [Full Text] [PDF]

				J. J. Hill, Y. Qiu, R. M. Hewick, and N. M. Wolfman Regulation of Myostatin in Vivo by Growth and Differentiation Factor-Associated Serum Protein-1: A Novel Protein with Protease Inhibitor and Follistatin Domains Mol. Endocrinol., June 1, 2003; 17(6): 1144 - 1154. [Abstract] [Full Text] [PDF]

				C. Vannahme, N. Smyth, N. Miosge, S. Gosling, C. Frie, M. Paulsson, P. Maurer, and U. Hartmann Characterization of SMOC-1, a Novel Modular Calcium-binding Protein in Basement Membranes J. Biol. Chem., October 4, 2002; 277(41): 37977 - 37986. [Abstract] [Full Text] [PDF]

				C. Welt, Y. Sidis, H. Keutmann, and A. Schneyer Activins, Inhibins, and Follistatins: From Endocrinology to Signaling. A Paradigm for the New Millennium Experimental Biology and Medicine, October 1, 2002; 227(9): 724 - 752. [Abstract] [Full Text] [PDF]

				S. A. Pangas, A. W. Rademaker, D. A. Fishman, and T. K. Woodruff Localization of the Activin Signal Transduction Components in Normal Human Ovarian Follicles: Implications for Autocrine and Paracrine Signaling in the Ovary J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2644 - 2657. [Abstract] [Full Text] [PDF]

				Y. Sidis, D. V. Tortoriello, W. E. Holmes, Y. Pan, H. T. Keutmann, and A. L. Schneyer Follistatin-Related Protein and Follistatin Differentially Neutralize Endogenous vs. Exogenous Activin Endocrinology, May 1, 2002; 143(5): 1613 - 1624. [Abstract] [Full Text] [PDF]

				D. V. Tortoriello, Y. Sidis, D. A. Holtzman, W. E. Holmes, and A. L. Schneyer Human Follistatin-Related Protein: A Structural Homologue of Follistatin with Nuclear Localization Endocrinology, August 1, 2001; 142(8): 3426 - 3434. [Abstract] [Full Text] [PDF]